The global innovative biopharma industry has historically been led by large multinational players with headquarters in the United States, Europe and Japan. Biopharma companies based in other countries ...

Two patients. Same hospital. Same diagnosis: lung cancer. Both receive the same chemotherapy. One responds well. The other doesn’t. For decades, cancer treatment followed a simple rule. Identify where ...

The US Supreme Court ruled yesterday, June 4, that pharmaceutical company Hikma’s generic cardiovascular drug does not infringe global biopharmaceutical company Amarin’s patents covering its drug ...

Healthcare costs figure strongly in California’s affordability crisis, with nearly 1 million Californians going to Mexico each year to purchase more affordable medical care and prescription drugs. To ...

Hims & Hers Health (HIMS) on Thursday announced the launch of generic versions of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy semaglutide through its telehealth platform in Canada. The ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...

A surge in demand since last year for estrogen patches to ease menopause symptoms has strained supplies and led to shortages, sparking a scramble for medicines that industry sources say could last up ...

The rapid entry of semaglutide generics is beginning to weigh on the growth of Eli Lilly’s tirzepatide brand Mounjaro, even as the broader market expands, data from pharma market intelligence and data ...

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...